Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Teva Pharmaceutical Industries Limited. A complete text table follows the diagram.
AUSTEDO, AJOVY and UZEDY are gradually rebuilding growth inside the world's largest generic-drug platform.
Swipe to explore
Named innovative-product revenue is summed across the filing's geographic product tables. 'Generic, legacy & other medicines' combines the remaining geographic-segment revenue and is an editorial arithmetic residual. Other Activities includes distribution and other operations reported separately by Teva.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Generic, legacy & other medicines | 1 | $2.6B | Still the foundation of Teva |
| AUSTEDO | 1 | $578M | Movement-disorder treatment |
| AJOVY | 1 | $196M | Migraine prevention |
| UZEDY | 1 | $63M | Long-acting schizophrenia treatment |
| Distribution & other activities | 1 | $584M | Anda and other operations |
| Teva net revenue | 2 | $4.0B | A hybrid generics-and-innovation portfolio |
| Operating income | 3 | $652M | Up 26% year over year |
| Manufacturing, R&D & commercialization | 3 | $3.3B | Global pharmaceutical platform |
| From | To | Value |
|---|---|---|
| Generic, legacy & other medicines | Teva net revenue | $2.6B |
| AUSTEDO | Teva net revenue | $578M |
| AJOVY | Teva net revenue | $196M |
| UZEDY | Teva net revenue | $63M |
| Distribution & other activities | Teva net revenue | $584M |
| Teva net revenue | Operating income | $652M |
| Teva net revenue | Manufacturing, R&D & commercialization | $3.3B |